Hanbio to Pursue Listing on Canadian Stock Market

[Asia Economy Reporter Myunghwan Lee] Hanbio Group announced on the 16th that it has signed a consulting contract with Canadian asset management company Blue Apple Asset Management to prepare for listing on the Canadian stock market.

[Photo by HanBio]

Hanbio is a cell-specialized bio company preparing for the development and commercialization of therapeutics using NK immune cells, stem cells, and mammary papilla cells, the company explained. Hanbio and Blue Apple Asset Management have been in close consultation since last year regarding the possibility of listing in advanced overseas financial markets. The two companies signed a contract to promote Hanbio's listing on the Canadian stock market (TXSV), expecting that advanced financial markets emphasize growth potential and business models.

Blue Apple Asset Management, headquartered in Vancouver, Canada, is an asset management firm that provides IPO consulting, mergers and acquisitions, corporate asset management, REIT funds, and alternative investments for companies worldwide. Ja Myung, CEO of Blue Apple Asset Management, emphasized in a special lecture at the inauguration ceremony of the World Korean Business Advisory Group last November that "It is the competitiveness of a company for Korea's high-potential companies to raise funds from overseas and establish a foundation for sustainable management through direct listing."

Hanbio Group explained that along with launching the Canadian listing preparation team and reorganizing the group, it has been strengthening excellent research and development personnel while focusing on product development using stem cell candidate materials.

This content was produced with the assistance of AI translation services.